Objective: To examine the effect of long-term administration of GnRH agonists (GnRHa) on PRL secretion, in children affected by central precocious puberty (CPP) and growth hormone deficiency (GHD). Design: Prospective analysis of blood sampling before, during, and after GnRHa treatments. Setting: Pediatric endocrine center. Patient(s): One hundred nineteen and 93 children with a diagnosis of CPP and GHD, respectively. Intervention(s): Monthly depot injections of GnRHa drugs (leuprorelin acetate 3.75 mg [LA] and triptorelin 3.75 mg [TR]) administered to CPP and GHD patients for 40 and 24 months, respectively. Main Outcome Measure(s): Serum PRL levels at baseline and after 6, 12, 18, 24, 30, 36, and 40 months of treatment with GnRHa were compared between CPP and GHD groups. PRL levels at 6 and 12 months after GnRHa withdrawal were also examined. Result(s): Although serum PRL levels tended to be higher in TR- than in LA-treated patients, no significant difference in circulating PRL in basal condition and during GnRHa treatment was detected between the CPP and GHD groups. However, five children (3.8%) developed hyperprolactinetnia during TR treatment. Conclusion(S): Although there are no general concerns about GnRHa treatment safety, careful PRL monitoring is required in GnRHa-treated children. (Fertil Steril((R)) 2005;84:719-24. (c) 2005 by American Society for Reproductive Medicine.)

Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children

FEDERICO, GIOVANNI;SAGGESE, GIUSEPPE
2005-01-01

Abstract

Objective: To examine the effect of long-term administration of GnRH agonists (GnRHa) on PRL secretion, in children affected by central precocious puberty (CPP) and growth hormone deficiency (GHD). Design: Prospective analysis of blood sampling before, during, and after GnRHa treatments. Setting: Pediatric endocrine center. Patient(s): One hundred nineteen and 93 children with a diagnosis of CPP and GHD, respectively. Intervention(s): Monthly depot injections of GnRHa drugs (leuprorelin acetate 3.75 mg [LA] and triptorelin 3.75 mg [TR]) administered to CPP and GHD patients for 40 and 24 months, respectively. Main Outcome Measure(s): Serum PRL levels at baseline and after 6, 12, 18, 24, 30, 36, and 40 months of treatment with GnRHa were compared between CPP and GHD groups. PRL levels at 6 and 12 months after GnRHa withdrawal were also examined. Result(s): Although serum PRL levels tended to be higher in TR- than in LA-treated patients, no significant difference in circulating PRL in basal condition and during GnRHa treatment was detected between the CPP and GHD groups. However, five children (3.8%) developed hyperprolactinetnia during TR treatment. Conclusion(S): Although there are no general concerns about GnRHa treatment safety, careful PRL monitoring is required in GnRHa-treated children. (Fertil Steril((R)) 2005;84:719-24. (c) 2005 by American Society for Reproductive Medicine.)
2005
Massart, F; Parrino, R; Placidi, G; Massai, G; Federico, Giovanni; Saggese, Giuseppe
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/180386
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 5
social impact